United Therapeutics (UTHR) EBT (2009 - 2026)

United Therapeutics has disclosed EBT across 18 years of filings, most recently posting $318.3 million for Q1 2026.

• EBT for Q1 2026 came in at $318.3 million, down 24.84% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 2.86% YoY), and the FY2025 annual result was $1.7 billion, up 11.36% from the prior year.
• EBT came in at $318.3 million for Q1 2026 at United Therapeutics, down from $444.0 million in the prior quarter.
• In the past five years, EBT ranged from a high of $444.0 million in Q4 2025 to a low of $150.6 million in Q2 2022.
• The 5-year median for EBT is $351.8 million (2023), against an average of $340.9 million.
• Peak annual rise in EBT reached 849.85% in 2022, while the deepest fall reached 30.44% in 2022.
• United Therapeutics' EBT stood at $178.8 million in 2022, then jumped by 65.21% to $295.4 million in 2023, then jumped by 34.22% to $396.5 million in 2024, then increased by 11.98% to $444.0 million in 2025, then fell by 28.31% to $318.3 million in 2026.
• The last three EBT figures came in at $318.3 million (Q1 2026), $444.0 million (Q4 2025), and $438.0 million (Q3 2025), per Business Quant data.